Payment overview · 2025
General Payments
$1,597.12
66 reported records · 13 companies
Healthcare provider profile · identity verified
Paul R Leva, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTHPORT, NY · NPI 1841222577
Verified facts
What the public records show
CMS Open Payments records show Paul R Leva, MD received $1,597.12 in general payments during 2025 across 66 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $613.30 | 38.4% | 28 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $236.04 | 14.8% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $144.35 | 9.0% | 5 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $126.85 | 7.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $120.49 | 7.5% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.20 | 4.7% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.08 | 4.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.43 | 3.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.16 | 3.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.05 | 2.7% | 2 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $33.50 | 2.1% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.55 | 1.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.12 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,592.12 | 65 |
| Education | $5.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $291.97 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $261.66 | 11 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $236.04 | 9 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $144.35 | 5 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $126.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $100.34 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.62 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.34 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.20 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.08 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $57.43 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $57.43 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.05 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.05 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.05 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $33.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 14 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 102 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 173 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
173 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 263 | 97 |
| Ozempic | Semaglutide | 173 | 31 |
| Alprazolam | Alprazolam | 157 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 145 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 128 | 46 |
| Metformin Hcl | Metformin Hcl | 127 | 44 |
| Montelukast Sodium | Montelukast Sodium | 120 | 50 |
| Clonazepam | Clonazepam | 111 | 24 |
| Farxiga | Dapagliflozin Propanediol | 102 | 19 |
| Tramadol Hcl | Tramadol Hcl | 101 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 28 |
| Losartan Potassium | Losartan Potassium | 83 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 34 |
| Gabapentin | Gabapentin | 72 | 26 |
| Omeprazole | Omeprazole | 72 | 29 |
| Methadone Hcl | Methadone Hcl | 69 | suppressed |
| Carvedilol | Carvedilol | 64 | 23 |
| Progesterone | Progesterone, Micronized | 64 | 17 |
| Famotidine | Famotidine | 63 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 24 |
| Vascepa | Icosapent Ethyl | 59 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 22 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 28 |
| Valsartan | Valsartan | 42 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 15 |
| Linzess | Linaclotide | 40 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 13 |
| Azithromycin | Azithromycin | 37 | 28 |
| Glimepiride | Glimepiride | 37 | 15 |
| Baclofen | Baclofen | 35 | 27 |
| Betamethasone Valerate | Betamethasone Valerate | 35 | 22 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 11 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 11 |
| Bupropion Xl | Bupropion Hcl | 31 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 11 |
| Donepezil Hcl | Donepezil Hcl | 30 | 12 |
| Lisinopril | Lisinopril | 30 | 11 |
| Finasteride | Finasteride | 29 | 11 |
| Levofloxacin | Levofloxacin | 29 | 21 |
| Metformin Hcl Er | Metformin Hcl | 29 | 12 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 20 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Np Thyroid | Thyroid,pork | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 14 |
| Lidocaine | Lidocaine | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 14 |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 14 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 17 |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Sucralfate | Sucralfate | 18 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Celecoxib | Celecoxib | 17 | suppressed |
| Furosemide | Furosemide | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Nateglinide | Nateglinide | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 13 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,597.12 · 66 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, CONTRAVE, DAXXIFY, FARXIGA, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tlando, Wegovy, Xeomin, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error